MTA2抗体;MTA2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: NIH/3T3, A431, 293T and Hela cell lysates, Primary antibody: P12576(MTA2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P12576(MTA2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The MTA2 (Metastasis-Associated Protein 2) antibody is a tool used to study the MTA2 protein, a member of the MTA family involved in epigenetic regulation and cancer progression. MTA2 functions as a core component of the NuRD (Nucleosome Remodeling and Deacetylation) complex, which modulates chromatin structure and gene expression through histone deacetylation and ATP-dependent chromatin remodeling. It plays a critical role in transcriptional repression, DNA repair, and cell cycle regulation.

MTA2 overexpression is linked to tumor metastasis, poor prognosis, and therapy resistance in cancers like breast, colorectal, and prostate. Its antibody enables detection and quantification of MTA2 in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding research into its oncogenic mechanisms. Studies using MTA2 antibodies have revealed its interaction with pathways like Wnt/β-catenin and HIF-1α, highlighting its role in promoting epithelial-mesenchymal transition (EMT) and angiogenesis.

Compared to other MTA family members (e.g., MTA1. MTA3), MTA2 exhibits distinct tissue-specific expression and regulatory functions. The antibody’s specificity ensures accurate differentiation of MTA2 isoforms, supporting investigations into its dual roles as a tumor suppressor or promoter depending on cellular context. Research utilizing MTA2 antibodies continues to advance understanding of epigenetic dysregulation in cancer, offering potential therapeutic targets.